An announcement from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics has announced an update on the sale of its subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Limited for US$10.8 million. The completion of this transaction depends on Pleiades finalizing certain licensing agreements and fundraising efforts, which are reportedly progressing well. Pleiades has successfully secured exclusive worldwide licenses for the PapMV cancer and infectious disease vaccine platform and the S100A9 immunotherapy, fulfilling a key condition for the sale. This transaction is expected to impact Roquefort’s operations by allowing the company to focus on executing further transactions for its other programs.
More about Roquefort Investments PLC
Roquefort Therapeutics is a Main Market listed biotech company focused on developing first in class drugs in the high value and high growth immunology and oncology markets. The company’s portfolio includes five novel patent-protected pre-clinical anti-cancer medicines, featuring Midkine antibodies, RNA and mRNA therapeutics, STAT-6 siRNA therapeutics, and MK cell therapy, all aimed at innovative anti-cancer treatments.
YTD Price Performance: -55.56%
Average Trading Volume: 1,457,433
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.44M
Learn more about ROQ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com